{"id":"dtic-dacarbazine","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (leukopenia, thrombocytopenia)"},{"rate":"90","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Alopecia"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"10-20","effect":"Flu-like syndrome"},{"rate":"1-5","effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DTIC is a prodrug that requires hepatic activation to its active form, methyl diazonium ion, which then alkylates DNA at multiple sites. This DNA damage triggers cell cycle arrest and programmed cell death, particularly in rapidly dividing malignant cells. It is non-phase-specific and can act on cells throughout the cell cycle.","oneSentence":"Dacarbazine is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:14.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Hodgkin lymphoma"},{"name":"Soft tissue sarcoma"}]},"trialDetails":[{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT05691491","phase":"PHASE1, PHASE2","title":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-28","conditions":"Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm","enrollment":58},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT03528642","phase":"PHASE1","title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-01","conditions":"Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3","enrollment":40},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":"Neoplasms, Child, Adolescent","enrollment":105},{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT05413304","phase":"PHASE1","title":"Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Glioma","enrollment":1},{"nctId":"NCT06413706","phase":"PHASE2","title":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-25","conditions":"Glioma","enrollment":45},{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT05843253","phase":"PHASE2","title":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-08-22","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":120},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT05384821","phase":"PHASE1, PHASE2","title":"Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2022-09-14","conditions":"Wilms Tumor","enrollment":28},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT06934889","phase":"PHASE1","title":"Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-07","conditions":"Glioblastoma, Gliosarcoma","enrollment":60},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04890093","phase":"PHASE1, PHASE2","title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-31","conditions":"Sarcoma, Ewing, Rhabdomyosarcoma","enrollment":64},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Glioblastoma","enrollment":65},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT06478212","phase":"PHASE1, PHASE2","title":"Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2025-01-22","conditions":"IDH1-mutant Glioma, IDH2-mutant Glioma","enrollment":51},{"nctId":"NCT06556563","phase":"PHASE3","title":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"NovoCure GmbH","startDate":"2025-02-03","conditions":"Glioblastoma","enrollment":741},{"nctId":"NCT03749187","phase":"PHASE1","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2019-04-03","conditions":"Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation","enrollment":78},{"nctId":"NCT04457284","phase":"PHASE2","title":"Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-18","conditions":"Colorectal Adenocarcinoma","enrollment":18},{"nctId":"NCT05440786","phase":"PHASE2","title":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-09-20","conditions":"Sarcoma, Ewing, Neoplasm Metastasis","enrollment":46},{"nctId":"NCT03257618","phase":"NA","title":"Quality of Life and Neurocognitive Functioning","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2017-07-27","conditions":"Glioma","enrollment":26},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT04919382","phase":"PHASE2","title":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2022-01-26","conditions":"Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":56},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT06681220","phase":"PHASE1, PHASE2","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-23","conditions":"Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT07104032","phase":"PHASE3","title":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-03","conditions":"Relapsed/Refractory Primary Central Nervous System Lymphoma","enrollment":132},{"nctId":"NCT06504381","phase":"PHASE1, PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":"High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma","enrollment":70},{"nctId":"NCT06639607","phase":"PHASE1, PHASE2","title":"PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma","enrollment":68},{"nctId":"NCT07457307","phase":"PHASE1","title":"Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-06","conditions":"High-grade Glioma","enrollment":20},{"nctId":"NCT07457775","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-31","conditions":"Soft Tissue Sarcoma (Excluding GIST)","enrollment":24},{"nctId":"NCT01336270","phase":"","title":"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-05","conditions":"Melanoma","enrollment":217},{"nctId":"NCT05188508","phase":"PHASE2","title":"Pembrolizumab, Olaparib, and Temozolomide for People With Glioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-01-14","conditions":"Glioma","enrollment":57},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT07452458","phase":"PHASE3","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2026-06-08","conditions":"Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma","enrollment":398},{"nctId":"NCT05004116","phase":"PHASE1, PHASE2","title":"A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-09","conditions":"Advanced Cancer, Metastatic Solid Tumor","enrollment":77},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT07195591","phase":"PHASE3","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","status":"RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2025-12-10","conditions":"Glioblastoma","enrollment":766},{"nctId":"NCT07444918","phase":"PHASE2","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-01","conditions":"Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)","enrollment":33},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT03519412","phase":"PHASE2","title":"Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status","status":"COMPLETED","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2019-01-23","conditions":"Colorectal Neoplasms, Microsatellite Instability","enrollment":107},{"nctId":"NCT06541262","phase":"PHASE1, PHASE2","title":"Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-10-30","conditions":"Neuroblastoma, Ewing Sarcoma, Osteosarcoma","enrollment":104},{"nctId":"NCT04238819","phase":"PHASE1, PHASE2","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-09","conditions":"Relapsed Solid Tumor, Refractory Solid Tumor","enrollment":47},{"nctId":"NCT05765812","phase":"PHASE1, PHASE2","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2023-05-15","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III","enrollment":116},{"nctId":"NCT01712490","phase":"PHASE3","title":"A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-11-09","conditions":"Hodgkin Lymphoma","enrollment":1334},{"nctId":"NCT06346067","phase":"PHASE3","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2024-04-29","conditions":"Advanced or Metastatic NRAS-mutant Melanoma","enrollment":78},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT01824875","phase":"PHASE2","title":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-08-08","conditions":"Gastrinoma, Glucagonoma, Insulinoma","enrollment":144},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT06831370","phase":"PHASE4","title":"A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-08-28","conditions":"Hodgkin Lymphoma","enrollment":124},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT02942264","phase":"PHASE1, PHASE2","title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-12-14","conditions":"Brain Tumor, Astrocytoma, Astroglioma","enrollment":53},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT03514069","phase":"PHASE1","title":"Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-06-05","conditions":"Glioma, Glioblastoma","enrollment":60},{"nctId":"NCT06448286","phase":"PHASE3","title":"PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-12-01","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT03033914","phase":"PHASE1, PHASE2","title":"A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-25","conditions":"Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT07085338","phase":"PHASE2","title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-11-10","conditions":"Neuroblastoma Recurrent","enrollment":54},{"nctId":"NCT05987332","phase":"PHASE2, PHASE3","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2023-10-31","conditions":"Metastatic Uveal Melanoma","enrollment":420},{"nctId":"NCT05095376","phase":"PHASE3","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-28","conditions":"Glioblastoma, Gliosarcoma","enrollment":265},{"nctId":"NCT06995872","phase":"PHASE1","title":"Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-21","conditions":"Neuroblastoma","enrollment":34},{"nctId":"NCT03529448","phase":"PHASE1, PHASE2","title":"TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2023-08-18","conditions":"Glioblastoma","enrollment":33},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT03830918","phase":"PHASE1, PHASE2","title":"Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-03-06","conditions":"Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":59},{"nctId":"NCT04307277","phase":"PHASE3","title":"Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2020-10-09","conditions":"Soft Tissue Sarcoma","enrollment":600},{"nctId":"NCT07400302","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2026-02-01","conditions":"Mucosal Melanoma, PD-L1 Positive","enrollment":220},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT04225390","phase":"PHASE2","title":"Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-01-13","conditions":"Immunotherapy","enrollment":38},{"nctId":"NCT04478279","phase":"PHASE1, PHASE2","title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sapience Therapeutics","startDate":"2020-07-01","conditions":"Glioblastoma, Melanoma Stage IV, Breast Cancer","enrollment":125},{"nctId":"NCT04901702","phase":"PHASE1, PHASE2","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-06-09","conditions":"Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":90},{"nctId":"NCT03405792","phase":"PHASE2","title":"Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-23","conditions":"Glioblastoma, Glioblastoma, WHO Grade IV","enrollment":40},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["detimedac"],"phase":"phase_3","status":"active","brandName":"DTIC (dacarbazine)","genericName":"DTIC (dacarbazine)","companyName":"University of Wuerzburg","companyId":"university-of-wuerzburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dacarbazine is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis in cancer cells. Used for Metastatic melanoma, Hodgkin lymphoma, Soft tissue sarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}